TRULANCE® (plecanatide) for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians

By Jeffrey Roberts
February 8, 2022 in IBS Medications, Medical Foods and Fecal Microbiota Transplantation (FMT)

Followers 1

Recommended Posts

Jeffrey Roberts

Posted February 8, 2022

- Report
- Share

Posted February 8, 2022

LAVAL, QC, Feb. 8, 2022 /CNW Telbec/ - Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE® (plecanatide).

TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and is the first treatment brought to market in Canada by the gastrointestinal division of the Company. Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment, but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms.

>> Read full press release